Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Novavax Inc (NVAX) Price & Performance

Global X Copper Miners ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Novavax Inc — how do they compare? Global X Copper Miners ETF trades at $89.57, while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

COPXNVAX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$95.70$11.19
52-Week Low
$46.08$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX, the Global X Copper Miners ETF, trades at $89.43, down slightly by 0.09% today. The technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels indicating overbought conditions. Recent news highlights institutional accumulation, with 180 Wealth Advisors increasing its stake by 28.1% in Q2 2026 (SEC filing, August 6, 2026). The ETF is positioned to benefit from copper demand driven by AI infrastructure and electrification trends.

The investment case for COPX hinges on structural copper demand growth from AI data centers and green energy, though it faces risks from commodity price volatility and mining supply constraints. Analysts view the recent pullback as a buying opportunity, citing operational leverage to copper prices. Key risks include cyclical mining downturns and execution challenges among constituent companies.

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Returns comparison

Trailing returns across standard periods

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX